Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
The Cancer Research UK Scotland Institute in Glasgow invites applications for a Postdoctoral Research Scientist to develop a PET radiotracer for HCC subtype imaging. The role focuses on radiochemistry, preclinical PET/MRI, and translating findings toward clinical studies.
You will work within a multidisciplinary team and contribute to independent research, data analysis, and manuscript preparation. Salary is from £39,253 to £45,505 plus relocation support; fixed term up to 6 years.
Salary:from £39,253 to 45,505 subject to experience, plus relocation allowance and visa costs if required.
Contract term:Fixed up to 6 years, subject to successful review at Year 3
The CRUK Scotland Institute is a cancer research institute, situated in Glasgow with approximately 250 researchers split across 30 research groups consisting of PIs, postdoctoral scientists, PhD students and scientific officers. It is one of Europe's leading cancer research centres, supporting cutting‑edge work into the molecular mechanisms of cancer development. As well as core support from Cancer Research UK, the Institute also receives an additional third of its total income from external grants and industry collaborations. It has an excellent reputation for fundamental cancer research, including world‑class metabolism studies and renowned in‑vivo modelling of tumour growth and metastasis.
Hepatocellular carcinoma (HCC) is a highly heterogeneous and often treatment‑resistant cancer, with no clinically validated biomarkers to guide patients toward the most effective targeted therapies. A clinically important HCC subtype driven by activation of the canonical Wnt/β‑catenin pathway is strongly immune‑evasive and frequently resistant to immunotherapy. Despite its significance, this subtype cannot currently be reliably identified using genetic profiling alone.
This Jules Thorne funded programme brings together a multidisciplinary team to develop the first subtype specific precision approach for HCC. The project integrates metabolic biomarker discovery and validation, state of the art GEMMs and patient derived organoid models, clinical sample analysis from prospective patient cohorts, and advanced radiochemistry and metabolic PET imaging. Together, these approaches aim to establish the first subtype specific therapeutic strategy for early phase HCC clinical trials.
We are seeking a highly motivated Postdoctoral Research Scientist to contribute to the development of a PET imaging probe targeting glutamine synthetase (GS), a downstream effector of canonical Wnt/β catenin signalling, to detect this tumour subtype in vivo. This project builds on the recent discovery of a noncanonical enzymatic function of GS (Villar et al., Nature Chemical Biology, 2023). The successful candidate will work on radiotracer synthesis, preclinical PET/MRI imaging, and ultimately clinical translation.
Postdocs are key members of our research community, and we offer them a range of opportunities to train and develop as researchers while they are with us:
Our vision is to build and maintain a diverse and inclusive research culture based on our shared values of Innovate, Respect, Integrity, Teamwork and Excellence. These values, which underpin our behaviours and everything we do, allow all our people to realise their full potential. The diversity of our staff and students is also what makes the Institute such a vibrant place to work and advance discoveries in cancer research. Family friendly policies, our collaborative ethos, a focus on good mental health and well‑being and opportunities for all help to create an enjoyable and inclusive workplace where your voice matters.
The Beatson Institute for Cancer Research, a Registered Scottish Charity NoSC006106 & Company Limited by Guarantee (Registered in Scotland No 84170) [trading as the Cancer Research UK Scotland Institute]